Some FreeStyle Libre 3 plus glucose monitor sensors may provide incorrect low glucose readings, Health Canada said in an alert. Abbott Diabetes Care recalled certain types of its FreeStyle Libre 3 and ...

FreeStyle Libre is a continuous glucose monitoring (CGM) system. It uses a sensor to read and check a person’s glucose levels. People with diabetes can use FreeStyle Libre to help manage the condition ...

Randomized clinical trial of Abbott's FreeStyle Libre 2 system compared to self-monitoring of blood glucose (SMBG) shows FreeStyle Libre 2 leads to significant reductions in glycated hemoglobin (HbA1c ...

Abbott Labs’ (NYSE:ABT) stock price could gain over 10% if its FreeStyle Libre system captures a 30% share of the blood glucose monitoring market by 2020, according to our estimates. FreeStyle Libre ...

The U.S. Food and Drug Administration today approved the FreeStyle Libre Flash Glucose Monitoring System, the first continuous glucose monitoring system that can be used by adult patients to make ...

ABBOTT PARK, Ill., Sept. 3, 2014 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that it has received CE Mark (Conformite Europeenne) for its FreeStyle ® Libre Flash Glucose Monitoring System, a ...

Abbott announced late-breaking clinical data that demonstrate the FreeStyle Libre 3 system has an overall mean absolute relative difference (MARD) of 7.9%, making it the first and only 14-day ...

Diabetes remains a serious chronic disease worldwide, affecting approximately 589 million people 3 and often accompanied by cardiovascular complications. 4 People with Type 1 and Type 2 diabetes are 2 ...

Use of the novel FreeStyle Libre glucose monitoring system (Abbott) leads to improved glycemic control among people with diabetes, new real-world data indicate. Findings from deidentified data for ...

(RTTNews) - Abbott (ABT) said late-breaking clinical data showed the FreeStyle Libre 3 system has an overall mean absolute relative difference (MARD) of 7.9%, making it the first and only 14-day ...

ABBOTT PARK, Ill., Feb. 16, 2016 /PRNewswire/ -- Today, Abbott (NYSE: ABT) announced that it has received approval from the Therapeutic Goods Administration (TGA) in Australia for its FreeStyle® Libre ...